Cholangiocarcinoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2] [3], Suveenkrishna Pothuru, M.B,B.S. [4]

The incidence of cholangiocarcinoma is approximately 1-2 per 100,000 individuals in the United States. The prevalence of cholangiocarcinoma is approximately 0.01% to 0.46% per 100,000 individuals. Patients of all age groups may develop cholangiocarcinoma. Cholangiocarcinoma is more common in males than in females.

• The incidence of cholangiocarcinoma is approximately 1-2 per 100,000 individuals in the United States.
• The highest annual incidences of cholangiocarcinoma is 5.5 cases per 100,000 people in Japan, and 7.3 cases per 100,000 people in Israel.^[1]

• The prevalence of cholangiocarcinoma is approximately 0.01% to 0.46% per 100,000 individuals.
• The prevalence of cholangiocarcinoma in patients with primary sclerosing cholangitis may be as high as 30%, based on autopsy studies.^[1][2]

• The mortality rate for intrahepatic cholangiocarcinoma among men increased from 0.17 to 0.78 per 100,000 in period of 1975-1979 to 1993-1997.^[3]
• The mortality rate for intrahepatic cholangiocarcinoma among women, increased from 0.12 to 0.57 per 100,000 in period of 1975-1979 to 1993-1997.

• Patients of all age groups may develop cholangiocarcinoma.
• The median age at the time of cholangiocarcinoma diagnosis is 70-80 years, except in patients with bile duct cystic disorders.^[4]
• Bile duct cystic disorders usually develop cholangiocarcinoma much earlier, between 30 and 40 years.

• Cholangiocarcinoma usually affects individuals of the American Indian, Alaska Natives and Asian and Pacific Islanders race.^[5]

• Cholangiocarcinoma is more common in males than in females.^[6]

• The majority of cholangiocarcinoma cases are reported in North America, Asia, and Australia.^[5]

Template:WH Template:WS